Key Takeaways: Junshi Biosciences reported dismal results in the first quarter, with operating income plunging nearly 60% and its net loss expanding by 37% Hopes of a big revenue boost from an oral Covid drug have been dashed, and the company may not recoup its investment in the short term By Molly Wen